First class action filed over Lemme GLP-1 Daily supplement claims

A proposed class action filed March 10, 2025 in federal court in New York accuses supplement brand Lemme of falsely advertising its GLP-1 Daily capsules, which are sold as a way to reduce hunger and support weight management by raising the body's own glucagon-like peptide-1. ^[1] The case, Robins v. Lemme Inc. (No. 1:25-cv-01938), is the first of two class actions against the product; a second was filed in California state court. ^[1][3]

Lemme was co-founded by Simon Huck and Kourtney Kardashian Barker, and GLP-1 Daily launched in September 2024 with marketing that it will "support your body's GLP-1 production, reduce hunger, and support healthy weight management." ^[2] The 17-page New York complaint says the company promises those benefits from a 17% increase in naturally occurring GLP-1 — and that Lemme has no clinical evidence that such an increase changes calorie intake, fullness or body weight. ^[1] A one-month supply costs $90, and a six-month subscription costs $378, according to the complaint. ^[1]

What the underlying research shows

The GLP-1 claim rests on Eriomin, a lemon extract standardized for eriocitrin made by Ingredients by Nature. ^[2] In a 2023 double-blind randomized trial in people with prediabetes, 200 mg a day for 12 weeks was linked to a 22% increase in GLP-1 blood levels and a 6% drop in glycemic levels; a separate randomized trial of 30 people with high blood sugar found 200 mg a day for 12 weeks raised GLP-1 by 17% and lowered blood glucose by 5%. ^[2] Ingredients by Nature says the ingredient "consistently" showed an average GLP-1 increase of 17.5% versus placebo across three studies. ^[2]

But that research did not show a decrease in body weight, body-mass index, waist-to-hip ratio or calorie intake, according to Eriomin's published research and the lawsuits. ^[2] The complaints also argue the studies used sample sizes "far too small to derive valid statistical conclusions." ^[3]

The filings lean heavily on pharmacology. Natural GLP-1 has a half-life of about one to two minutes, while injected semaglutide — sold as Ozempic, Wegovy and Rybelsus — has a half-life of roughly seven days because its amino acid sequence was modified to resist the enzymes that break the hormone down. ^[1][2] The complaints say a 1 mg weekly dose of Ozempic or Wegovy produces blood concentrations "300,000% to 600,000% greater" than the body's resting level and lasting more than 5,000 times longer. ^[2][3] They also note GLP-1 rises roughly 400% to 900% after a meal on its own, making a 17% bump unlikely to move the needle. ^[3]

The named plaintiff, a California resident, says she would not have bought the product had she known the weight-loss claims lacked clinical support, and says she gained five pounds while taking it. ^[1] The proposed class covers U.S. residents who bought GLP-1 Daily from LemmeLive.com for personal use. ^[1]

The two filings do not line up neatly on timing. ClassAction.org lists the New York case as filed March 10, 2025 ^[1], while a later trade report says the California case was filed in February and was a refiling after the New York court was found to lack jurisdiction. ^[2] The plaintiff's lawyer, Tom Warren of Warren Terzian LLP, said the New York court lacked jurisdiction. ^[2] Lemme did not respond to a request for comment. ^[2] Rob Brewster, president of Ingredients by Nature, said the company does not comment on pending litigation involving finished products with multiple ingredients but "absolutely stand[s] behind our ingredient and our science." ^[2]

Why it matters for patients

The case spotlights a fast-growing category of over-the-counter products marketed alongside prescription GLP-1 drugs. GLP-1 Daily also contains Morosil, a blood orange extract with published research showing improved BMI and reduced fat versus placebo, and Supresa, a saffron extract with research on reduced snacking frequency and greater weight loss versus placebo. ^[2] The lawsuits target the GLP-1 messaging specifically, not every ingredient claim. ^[2]

Oversight has been thin. The FDA has issued only one warning letter to a supplement company over GLP-1-related claims, according to SupplySide Supplement Journal. ^[2] Attorney Marc Ullman of Rivkin Radler said "most enforcement seems to have fallen to the class action bar … and that's not a good situation," because silence from regulators leaves the limits on claims unclear. ^[2] Attorney Theodora McCormick of Baker Donelson noted that class actions normally follow FDA warning letters. ^[2]

One concrete change: the "un-hunger hormone" graphic the complaints cited has been removed from Lemme's website, per a review by the trade publication. ^[2] No ruling on the merits has been reported in these sources, and the outcome of either case is not yet known.